Goldman Sachs
VRCA icon

Goldman Sachs’s Verrica Pharmaceuticals VRCA Stock Holding History

Goldman Sachs’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,621
Closed -$155K – 7019
2025
Q4 		$155K Buy
+18,621
New +$103K ﹤0.01% 6107
2025
Q3 		– Sell
-17,528
Closed -$92.9K – 6671
2025
Q2 		$92.9K Buy
17,528
+3,622
+26% +$19.5K ﹤0.01% 5830
2025
Q1 		$61.5K Buy
13,906
+2,631
+23% +$17K ﹤0.01% 5861
2024
Q4 		$78.9K Buy
11,275
+3,219
+40% +$35.4K ﹤0.01% 5801
2024
Q3 		$117K Buy
+8,056
New +$363K ﹤0.01% 5556
2024
Q2 		– Sell
-1,956
Closed -$116K – 5949
2024
Q1 		$116K Buy
+1,956
New +$108K ﹤0.01% 5224
2023
Q4 		– Sell
-1,386
Closed -$53.8K – 5868
2023
Q3 		$53.8K Sell
1,386
-774
-36% -$39.3K ﹤0.01% 5273
2023
Q2 		$125K Sell
2,160
-4,857
-69% -$295K ﹤0.01% 5318
2023
Q1 		$456K Buy
+7,017
New +$424K ﹤0.01% 4872
2022
Q4 		– Sell
-1,759
Closed -$51K – 6288
2022
Q3 		$51K Sell
1,759
-1,416
-45% -$48.5K ﹤0.01% 5800
2022
Q2 		$61K Buy
3,175
+2,095
+194% +$105K ﹤0.01% 5986
2022
Q1 		$88K Buy
+1,080
New +$89K ﹤0.01% 6144
2020
Q1 		– Sell
-3,339
Closed -$531K – 5584
2019
Q4 		$531K Buy
3,339
+814
+32% +$120K ﹤0.01% 4471
2019
Q3 		$373K Buy
+2,525
New +$281K ﹤0.01% 4582
2018
Q3 		– Sell
-5,071
Closed -$1M – 5802
2018
Q2 		$1M Buy
+5,071
New +$993K ﹤0.01% 4075

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's VRCA Position: Q1 2026 in Review

Goldman Sachs sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 18,621 shares — an estimated $155K sold.

Goldman Sachs first reported a position in VRCA in Q2 2018 and held it in 15 quarters. The position peaked at $1M in Q2 2018. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Goldman Sachs reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 18,621 Verrica Pharmaceuticals shares in Q1 2026, an estimated $155K.
  • Goldman Sachs first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 15 quarters.
  • Goldman Sachs's Verrica Pharmaceuticals position peaked at $1M in Q2 2018.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.